Person:
ATAGÜNDÜZ, IŞIK

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ATAGÜNDÜZ

First Name

IŞIK

Name

Filters

2020 - 20244
Reset filters

Settings

Start date: 2020 × Has files: true ×

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    PublicationOpen Access
    Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment
    (SPRINGER LONDON LTD, 2020-07) ATAGÜNDÜZ, IŞIK; Soy, Mehmet; Keser, Gokhan; Atagunduz, Pamir; Tabak, Fehmi; Atagunduz, Isik; Kayhan, Servet
    COVID-19 infection has a heterogenous disease course
  • Thumbnail Image
    PublicationOpen Access
    Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic
    (SPRINGER HEIDELBERG, 2021-01) ATAGÜNDÜZ, IŞIK; Soy, Mehmet; Atagunduz, Pamir; Atagunduz, Isik; Sucak, Gulsan Turkoz
    Hemophagocytic syndrome (HPS) or hemophagocytic lymphohistiocytosis (HLH) is an acute and rapidly progressive systemic inflammatory disorder characterized by cytopenia, excessive cytokine production, and hyperferritinemia. Common clinical manifestations of HLH are acute unremitting fever, lymphadenopathy, hepatosplenomegaly, and multiorgan failure. Due to a massive cytokine release, this clinical condition is considered as a cytokine storm syndrome. HPS has primary and acquired (secondary, reactive) forms. Its primary form is mostly seen in childhood and caused by various mutations with genetic inheritance and, therefore, is called familial HLH. Secondary HLH may be caused in the presence of an underlying disorder, that is, secondary to a malignant, infectious, or autoimmune/autoinflammatory stimulus. This paper aims to review the pathogenesis and the clinical picture of HLH, and its severe complication, the cytokine storm, with a special emphasis on the developed classification criteria sets for rheumatologists, since COVID-19 infection has clinical symptoms resembling those of the common rheumatologic conditions and possibly triggers HLH. MED-LINE/Pubmed was searched from inception to April 2020, and the following terms were used for data searching: hemophagocytic syndrome OR macrophage activation syndrome OR hemophagocytic lymphohistiocytosis, OR cytokine storm. Finally, AND COVID-19 was included in this algorithm. The selection is restricted to the past 5 years and limited numbers of earlier key references were manually selected. Only full-text manuscripts, published in an English language peer-reviewed journal were included. Manuscript selection procedure and numbers are given in Fig. 2. Briefly, the database search with the following terms of Hemophagocytic syndrome OR Macrophage activation syndrome OR Hemophagocytic lymphohistiocytosis OR Cytokine storm yielded 6744 results from inception to April 2020. The selection is restricted to the past 5 years and only limited numbers of earlier key references were selected, and this algorithm resulted in 3080 manuscripts. The addition of (AND COVID-19) resulted in 115 publications of which 47 studies, together with four sections of an online book were used in the final review. No statistical method was used. HLH is triggered by genetic conditions, infections, malignancies, autoimmune-autoinflammatory diseases, and some drugs. In COVID-19 patients, secondary HLH and cytokine storm may be responsible for unexplained progressive fever, cytopenia, ARDS, neurological and renal impairment. Differentiation between the primary and secondary forms of HLH is utterly important, since primary form of HLH requires complicated treatments such as hematopoietic stem cell transplantation. Further studies addressing the performance of HScore and other recommendations in the classification of these patients is necessary.
  • Thumbnail Image
    PublicationOpen Access
    The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia
    (2023-01-01) DEMİRTAŞ, DERYA; YANIK, AHMET MERT; ATAGÜNDÜZ, IŞIK; TOPTAŞ, TAYFUR; Candan O., Demirtas D., YANIK A. M., ATAGÜNDÜZ I., TOPTAŞ T.
  • Thumbnail Image
    PublicationOpen Access
    Peripheral T-Cell Lymphoma Coexisting with Autoimmune Hemolytic Anemia: Analysis of Clinical Features
    (2024-01-01) DEMİRTAŞ, DERYA; YANIK, AHMET MERT; YILMAZ, ASU FERGÜN; ATAGÜNDÜZ, IŞIK; TUĞLULAR, AYŞE TÜLİN; TOPTAŞ, TAYFUR; Candan O., Naghizada N., DEMİRTAŞ D., YANIK A. M., Salim S., Menguc M. U., Arikan F., YILMAZ A. F., ATAGÜNDÜZ I., TUĞLULAR A. T., et al.
    Autoimmune hemolytic anemia (AIHA) is characterized by the production of antibodies targeting red blood cells (RBCs) antigens. The diagnosis is based on the presence of a hemolytic anemia with a positive direct antiglobulin test (or Coombs test) and on the absence of any other hereditary or acquired cause of hemolysis, although direct antiglobulin test-negative cases are not quite uncommon (5% of 308 cases of AIHA recently reported by the Gruppo Italiano Malattie EMatologiche dell’Adulto [GIMEMA]) [1, 2]. AIHA can present in primary and secondary forms. Secondary AIHA generally includes factors such as connective tissue diseases, drugs, infections, and lymphomas [3]. Cases of AIHA accompanied by lymphoma are rare and are typically presented in the literature as case reports. Roughly one-fifth of AIHA patients have lymphoma, while 7–10% of lymphoma patients have co-existing AIHA, indicating a clinicopathological link between both diseases [4–6]. In clinical settings, AIHA is commonly associated with indolent B-cell lymphomas, whereas the combination of AIHA with peripheral T-cell lymphoma (PTCL) is rarely observed [7–11]. This study retrospectively analyzes the clinical data, laboratory characteristics, treatment processes, and prognosis of five patients with the coexistence of PTCL and AIHA who were diagnosed within the last 10 years in our center.